Why antibiotics alone are often not enough and which options are truly supported by science.
Burning during urination, constant urinary urgency, and lower abdominal pain – no sooner have you finished the last antibiotic tablet than it starts all over again. Recurrent urinary tract infections (UTIs) are among the most common and distressing complaints in urological practice. Many women are prescribed antibiotics several times a year without ever breaking the cycle.
Yet the key to long-term relief rarely lies in the next prescription, but in answering one fundamental question: Why are bacteria able to colonize the urinary tract repeatedly in the first place? Modern urology relies on a multi-layered approach – ranging from targeted mucosal care and hormonal support to evidence-based non-antibiotic prevention strategies.
What defines a recurrent urinary tract infection?
According to the European Association of Urology (EAU), recurrent cystitis is defined as at least two infections within six months or three infections within one year.
The primary culprit is usually the intestinal bacterium Escherichia coli (E. coli), which uses fine hair-like structures (fimbriae) to anchor itself to the bladder lining. However, not every burning sensation indicates a new bacterial infection:
- Confirming the diagnosis: Before starting treatment, a urine culture should be performed to identify the exact pathogen and check for antibiotic resistance.
- Looking beyond the bladder: Local estrogen deficiency, inflammatory skin conditions of the vulva (such as lichen sclerosus), incomplete bladder emptying, or bladder pain syndrome can cause remarkably similar symptoms.
- Further diagnostics: Cystoscopy (bladder endoscopy) or imaging is not necessary for every patient, but is used selectively in atypical cases, when blood is present in the urine, or when specific risk factors exist.
Local estrogen therapy – the most important lever after menopause
After menopause, estrogen levels drop – a shift that affects not only the vagina, but also the urethra and the base of the bladder. The mucous membranes become thinner, drier, and more fragile. At the same time, protective lactic acid bacteria (lactobacilli) decline, the vaginal pH rises, and intestinal bacteria can easily take hold. Specialists refer to this condition as genitourinary syndrome of menopause (GSM).
How local estrogens protect:
- Locally applied estriol or estradiol (as a vaginal cream, suppository, or vaginal tablet) rebuilds the mucosal epithelium and restores the acidic, lactobacilli-protected environment.
- Clinical trials demonstrate a marked reduction in infection rates – the EAU gives this treatment a strong recommendation.
- An important distinction: Systemic absorption into the bloodstream is minimal with low-dose local preparations. Conversely, systemic hormone replacement therapy (oral tablets or skin patches) is not suitable as a standalone measure to prevent UTIs.
Lichen sclerosus – when the burning does not come from the bladder
Lichen sclerosus is a chronic inflammatory, non-contagious skin condition affecting the genital area. Typical symptoms include itching, burning, tiny skin fissures, and whitish discoloration of the skin. Especially after menopause, it frequently coexists with estrogen deficiency. When inflammation surrounds the urethral opening, every trip to the bathroom feels like a bladder infection – even when the urine is completely sterile.
The right treatment sequence:
- Cortisone to control inflammation: The gold standard for active lichen sclerosus is a high-potency topical corticosteroid ointment (e.g., clobetasol propionate 0.05%).
- Estrogen for mucosal support: Corticosteroids and local estrogens complement each other, but neither replaces the other. In clinical practice, when the skin is severely irritated or fissured, it is often advisable to calm the inflammation with cortisone first before introducing estrogen creams, which can otherwise cause intense stinging on broken skin.
An accurate clinical examination spares affected women years of unnecessary antibiotic courses.
Antibiotics – as targeted as possible, as little as necessary
For a confirmed acute bacterial bladder infection, antibiotics remain an important and fast-acting option. However, choosing the right agent is crucial:
- First-line therapy: The EAU specifically recommends nitrofurantoin, fosfomycin trometamol, or pivmecillinam (internationally also nitroxoline).
- Avoiding reserve antibiotics: Broad-spectrum antibiotics such as fluoroquinolones (e.g., ciprofloxacin) should not be used for uncomplicated cystitis due to potential side effects and resistance development.
- Do not treat bacteria without symptoms: So-called asymptomatic bacteriuria (bacteria in the urine without symptoms) does not require antibiotics in non-pregnant women – exceptions apply only during pregnancy and prior to certain urological procedures.
When is long-term antibiotic prophylaxis considered?
If non-antibiotic measures prove insufficient, low-dose prophylaxis over 3 to 12 months may be considered (e.g., nitrofurantoin 50–100 mg daily, trimethoprim 100 mg daily, or fosfomycin 3 g every 7–10 days). For infections clearly triggered by sexual intercourse, a single dose taken right afterward (postcoital prophylaxis) is often sufficient. For well-informed patients, physician-guided self-start therapy at the onset of typical symptoms is another flexible option.

Recurrent urinary tract infections require more than repeated courses of antibiotics. What matters is investigating possible causes, targeted treatment and individually tailored prevention.
Non-antibiotic alternatives: a reality check
Many women prefer effective ways to prevent UTIs without antibiotics. In recent years, science has scrutinized numerous supplements and home remedies – with some surprising results.
1. Methenamine hippurate – strong scientific backing
Methenamine hippurate is excreted via the kidneys and releases locally active formaldehyde in acidic urine, against which bacteria do not develop classic antibiotic resistance.
- Clinical evidence: In the landmark British ALTAR trial (240 women over 12 months), methenamine hippurate proved statistically non-inferior to daily low-dose antibiotic prophylaxis (1.38 vs. 0.89 infections per year).
- Recommendation: The EAU gives this active ingredient a strong recommendation for women without anatomical urinary tract abnormalities.
- Note for Switzerland: As no preparation is currently regularly registered with Swissmedic, it is obtained via international pharmacies on medical prescription.
2. Urine acidification, vitamin C, and lemon water – myth vs. fact
The idea sounds logical: bacteria dislike acidity, so acidifying the urine should stop them. Scientifically, however, this concept only holds up to a limited extent:
- L-Methionine: This sulfur-containing amino acid does lower urinary pH, but clinical data on infection prevention remain inconsistent. Furthermore, long-term use can be problematic in patients prone to certain kidney stones (uric acid or cystine stones). In Switzerland, Acimethin® was discontinued in 2026; alternatives such as Acimol® are available via import.
- Vitamin C (ascorbic acid): Neither reliably nor sustainably lowers urinary pH in everyday practice. Even when combined with methenamine, vitamin C showed no added benefit according to the current US guideline (AUA 2025) – whereas high doses increase the risk of oxalate kidney stones in predisposed individuals.
- Lemon water: Tastes sour, but once citrate is metabolized in the body, it actually has an alkalizing effect (making urine less acidic). Still, lemon water remains a great way to encourage higher fluid intake.
3. D-mannose – plausible theory, sobering trial data
The simple sugar D-mannose is thought to bind E. coli bacteria in the urine and prevent them from attaching to the bladder wall. However, a large randomized, placebo-controlled trial published in 2024 involving 598 women delivered sobering results: after six months, 51.0% of women taking D-mannose and 55.7% taking placebo experienced another UTI – no statistically significant difference. Consequently, the EAU assigns D-mannose only a weak recommendation due to conflicting evidence.
4. Cranberry, lingonberry and herbal combinations
- Cranberry: A major Cochrane review (2023) found a relative risk reduction of roughly 26% in women with recurrent UTIs. Important: These findings apply to the American cranberry (Vaccinium macrocarpon) standardized for proanthocyanidins – not automatically to every European lingonberry product.
- Canephron® (BNO 1045): Combining centaury, lovage root, and rosemary leaves, this herbal medicine exerts anti-inflammatory and antispasmodic effects and can help reduce antibiotic use according to clinical trials (weak EAU recommendation).
- Cystinol® (bearberry leaves): Contains antibacterial arbutin, but per Swiss prescribing information may only be used for up to 7 days for acute symptoms and is not suitable for long-term prevention.
5. Immunoprophylaxis ("bladder vaccines")
Immunomodulatory preparations train the body's own immune defenses against common urinary pathogens:
- Uro-Vaxom® (OM-89): Oral capsules containing E. coli extracts (regularly available in Switzerland).
- Uromune® (MV140): Sublingual spray containing four inactivated main pathogens – currently the most promising option in clinical trials (available in Switzerland via import).
- StroVac®: Injectable vaccine containing various bacterial strains (also available via import).
Assessment: Because overall global trial data remain heterogeneous, the EAU currently recommends immunotherapies primarily within controlled clinical studies or as an individualized option once standard measures have been exhausted.
6. Bladder instillations (rebuilding the GAG layer)
In stubborn cases, the protective lining of the inner bladder wall (glycosaminoglycan layer) can be rebuilt directly via a thin catheter using hyaluronic acid and chondroitin sulfate (e.g., iAluRil®). The EAU considers this a useful second-line option (weak recommendation) when less invasive measures fall short.
Overview: treatment options compared scientifically
| Measure | Mechanism of action | Scientific evidence (EAU) | Availability in Switzerland |
|---|---|---|---|
| Local estrogens | Rebuilds mucosa and lactobacilli flora | Very high (strong recommendation in postmenopausal women) | Regularly approved (prescription) |
| Methenamine hippurate | Local disinfection in acidic urine | High (strong recommendation, non-inferior to antibiotics) | Via international pharmacy (prescription) |
| Antibiotic prophylaxis | Targeted bacterial suppression | High (strong recommendation, risk of resistance/side effects) | Regularly approved (prescription) |
| Cranberry preparations | Inhibits bacterial adhesion (PAC) | Moderate (~26% risk reduction, product quality matters) | Over-the-counter |
| Herbal therapies | Anti-inflammatory / antibiotic-sparing | Low to moderate (weak recommendation) | Regularly approved (pharmacy/drugstore) |
| Bladder instillations | Regenerates protective bladder lining | Low to moderate (weak recommendation, second-line) | Specialist administration |
| Immunoprophylaxis | Stimulates mucosal immunity | Heterogeneous (promising, especially MV140) | Uro-Vaxom® regular; MV140/StroVac® import |
| D-mannose | Binds E. coli | Conflicting (large 2024 trial showed no significant benefit) | Over-the-counter |
| Vitamin C / lemon | Urine acidification | Unproven (not recommended for prophylaxis) | Over-the-counter |
What you can do in everyday life
- Increase fluid intake: Women with low baseline fluid intake can demonstrably lower their infection risk by drinking an additional 1.5 liters of water per day.
- Keep intimate hygiene gentle: Lukewarm water and pH-neutral, fragrance-free wash syndets are plenty. Vaginal douches and harsh intimate washes disrupt the natural protective flora.
- Review contraception: Spermicidal gels or diaphragms promote UTIs and should be reconsidered if infections recur.
- Empty the bladder calmly: Take your time when urinating without straining so that no residual urine remains in the bladder.
Our treatment approach at Urologie Zentrum Hergiswil
Every woman brings a unique medical history: treating a young woman experiencing infections after intercourse differs fundamentally from caring for a postmenopausal patient with fragile mucous membranes or an undiagnosed lichen sclerosus.
At Urologie Zentrum Hergiswil, we therefore avoid one-size-fits-all prescriptions in favor of a structured evaluation:
- Precise diagnostics using urine culture, post-void residual measurement, and careful clinical examination of the mucous membranes.
- Cause-oriented therapy addressing hormonal, dermatological, and functional factors alike.
- Antibiotic-sparing prevention tailored to current scientific evidence and your individual lifestyle.
Our goal is to break the cycle of recurring infections for good – so you can enjoy everyday life carefree once again.
Last updated: November 2026. This article is for medical information purposes and does not replace an individual medical examination. Immediate medical evaluation is required in case of fever, flank pain, chills, or a marked deterioration in general condition.
Scientific references
- European Association of Urology (EAU). EAU Guidelines on Urological Infections 2026 – Chapter 3.5: Recurrent cystitis. uroweb.org.
- AUA/CUA/SUFU. Updates to Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline (2025). J Urol. 2025. DOI: 10.1097/JU.0000000000004723.
- German Dermatological Society (DDG) et al. Evidence- and Consensus-Based S3 Guideline on Lichen Sclerosus. J Dtsch Dermatol Ges. 2026. DOI: 10.1111/ddg.70000.
- Harding C et al. Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women (ALTAR). BMJ. 2022;376:e068229. DOI: 10.1136/bmj-2021-068229.
- Hayward GN et al. D-Mannose for Prevention of Recurrent Urinary Tract Infection Among Women: A Randomized Clinical Trial. JAMA Intern Med. 2024;184(6):619–628. DOI: 10.1001/jamainternmed.2024.0264.
- Williams G et al. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2023;11(11):CD001321. DOI: 10.1002/14651858.CD001321.pub6.
- Mak Q et al. Bacterial Vaccines for the Management of Recurrent Urinary Tract Infections: A Systematic Review and Meta-analysis. Eur Urol Open Sci. 2024;62:39–50.
- Wagenlehner FME et al. Non-Antibiotic Herbal Therapy (BNO 1045) versus Antibiotic Therapy (Fosfomycin Trometamol) for the Treatment of Acute Lower Uncomplicated Urinary Tract Infections in Women. Urol Int. 2018;101(3):327–336.
- Damiano R et al. Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial. Eur Urol. 2011;59(4):645–651.
- Swissmedic Drug Information. Prescribing Information Cystinol®.
Next step
With a GP, HMO or telemedicine insurance model, you usually need a referral.